Announcement • Jun 01
Medikit Co.,Ltd. to Report Q1, 2027 Results on Aug 07, 2026 Medikit Co.,Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026 Reported Earnings • May 20
Full year 2026 earnings released: EPS: JP¥206 (vs JP¥205 in FY 2025) Full year 2026 results: EPS: JP¥206. Revenue: JP¥23.8b (up 5.4% from FY 2025). Net income: JP¥3.01b (flat on FY 2025). Profit margin: 13% (in line with FY 2025). Announcement • May 15
Medikit Co.,Ltd., Annual General Meeting, Jun 25, 2026 Medikit Co.,Ltd., Annual General Meeting, Jun 25, 2026. Announcement • May 10
Medikit Co.,Ltd. to Report Fiscal Year 2026 Results on May 15, 2026 Medikit Co.,Ltd. announced that they will report fiscal year 2026 results at 3:00 PM, Tokyo Standard Time on May 15, 2026 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 29 June 2026. Payout ratio is a comfortable 45% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.2%). Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: JP¥60.94 (vs JP¥59.67 in 3Q 2025) Third quarter 2026 results: EPS: JP¥60.94 (up from JP¥59.67 in 3Q 2025). Revenue: JP¥6.55b (up 8.1% from 3Q 2025). Net income: JP¥886.0m (up 1.0% from 3Q 2025). Profit margin: 14% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 7% per year. Announcement • Nov 29
Medikit Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026 Medikit Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026 Reported Earnings • Nov 15
Second quarter 2026 earnings released: EPS: JP¥65.50 (vs JP¥58.96 in 2Q 2025) Second quarter 2026 results: EPS: JP¥65.50 (up from JP¥58.96 in 2Q 2025). Revenue: JP¥6.03b (up 6.6% from 2Q 2025). Net income: JP¥958.0m (up 9.7% from 2Q 2025). Profit margin: 16% (in line with 2Q 2025). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year. Announcement • Nov 13
Medikit Co.,Ltd. (TSE:7749) announces an Equity Buyback for 250,000 shares, representing 1.71% for ¥409.8 million. Medikit Co.,Ltd. (TSE:7749) announces a share repurchase program. Under the program, the company will repurchase up to 250,000 shares, representing 1.71% of its share capital, for ¥409.8 million. The shares will be repurchased at ¥2,732 per share. The company will repurchase its shares in order to implement flexible capital policies in response to changes in the business environment, to improve capital efficiency, and as part of shareholder return measures. As of September 30, 2025, the company had 14,628,087 shares outstanding (excluding treasury shares) and 1,251,913 shares in treasury. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 29 September 2025. Payment date: 17 December 2025. Payout ratio is a comfortable 44% but the company is not cash flow positive. Trailing yield: 3.7%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.4%). Announcement • Sep 01
Medikit Co.,Ltd. to Report Q2, 2026 Results on Nov 12, 2025 Medikit Co.,Ltd. announced that they will report Q2, 2026 results on Nov 12, 2025 Reported Earnings • Aug 09
First quarter 2026 earnings released: EPS: JP¥26.82 (vs JP¥27.37 in 1Q 2025) First quarter 2026 results: EPS: JP¥26.82 (down from JP¥27.37 in 1Q 2025). Revenue: JP¥5.89b (up 4.7% from 1Q 2025). Net income: JP¥392.0m (down 3.2% from 1Q 2025). Profit margin: 6.7% (down from 7.2% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 4% per year. Announcement • May 31
Medikit Co.,Ltd. to Report Q1, 2026 Results on Aug 08, 2025 Medikit Co.,Ltd. announced that they will report Q1, 2026 results on Aug 08, 2025 Reported Earnings • May 20
Full year 2025 earnings released: EPS: JP¥205 (vs JP¥188 in FY 2024) Full year 2025 results: EPS: JP¥205. Revenue: JP¥22.6b (up 3.2% from FY 2024). Net income: JP¥3.01b (down 1.8% from FY 2024). Profit margin: 13% (in line with FY 2024). Announcement • May 15
Medikit Co.,Ltd., Annual General Meeting, Jun 26, 2025 Medikit Co.,Ltd., Annual General Meeting, Jun 26, 2025. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥45.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 27 June 2025. Payout ratio is a comfortable 43% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.1%). Announcement • Mar 01
Medikit Co.,Ltd. to Report Fiscal Year 2025 Results on May 15, 2025 Medikit Co.,Ltd. announced that they will report fiscal year 2025 results on May 15, 2025 Reported Earnings • Feb 12
Third quarter 2025 earnings released: EPS: JP¥59.67 (vs JP¥48.29 in 3Q 2024) Third quarter 2025 results: EPS: JP¥59.67 (up from JP¥48.29 in 3Q 2024). Revenue: JP¥6.06b (flat on 3Q 2024). Net income: JP¥877.0m (up 8.1% from 3Q 2024). Profit margin: 14% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year. Announcement • Nov 30
Medikit Co.,Ltd. to Report Q3, 2025 Results on Feb 10, 2025 Medikit Co.,Ltd. announced that they will report Q3, 2025 results on Feb 10, 2025 Reported Earnings • Nov 13
Second quarter 2025 earnings released: EPS: JP¥58.96 (vs JP¥45.02 in 2Q 2024) Second quarter 2025 results: EPS: JP¥58.96 (up from JP¥45.02 in 2Q 2024). Revenue: JP¥5.66b (up 6.8% from 2Q 2024). Net income: JP¥873.0m (up 16% from 2Q 2024). Profit margin: 15% (up from 14% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year. Announcement • Nov 11
Medikit Co.,Ltd. (TSE:7749) announces an Equity Buyback for 250,000 shares, representing 1.69% for ¥711.75 million. Medikit Co.,Ltd. (TSE:7749) announces a share repurchase program. Under the program, the company will repurchase up to 250,000 shares, representing 13.1% of its share capital, for ¥711.75 million. The company will repurchase its shares in order to implement flexible capital policies in response to changes in the business environment, to improve capital efficiency, and to return profits to shareholders. The program will be valid till February 28, 2025. As of September 30, 2024, the company had 14,809,307 shares outstanding (excluding treasury shares) and 3,070,693 shares in treasury. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥45.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 18 December 2024. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (1.0%). Announcement • Aug 28
Medikit Co.,Ltd. to Report Q2, 2025 Results on Nov 11, 2024 Medikit Co.,Ltd. announced that they will report Q2, 2025 results on Nov 11, 2024 Reported Earnings • Aug 11
First quarter 2025 earnings released: EPS: JP¥27.37 (vs JP¥33.60 in 1Q 2024) First quarter 2025 results: EPS: JP¥27.37 (down from JP¥33.60 in 1Q 2024). Revenue: JP¥5.63b (up 1.4% from 1Q 2024). Net income: JP¥405.0m (down 28% from 1Q 2024). Profit margin: 7.2% (down from 10% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year. Announcement • Jun 02
Medikit Co.,Ltd. to Report Q1, 2025 Results on Aug 09, 2024 Medikit Co.,Ltd. announced that they will report Q1, 2025 results on Aug 09, 2024 Reported Earnings • May 20
Full year 2024 earnings released: EPS: JP¥188 (vs JP¥171 in FY 2023) Full year 2024 results: EPS: JP¥188 (up from JP¥171 in FY 2023). Revenue: JP¥21.9b (up 1.1% from FY 2023). Net income: JP¥3.07b (up 7.2% from FY 2023). Profit margin: 14% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • May 17
Medikit Co.,Ltd., Annual General Meeting, Jun 26, 2024 Medikit Co.,Ltd., Annual General Meeting, Jun 26, 2024. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥35.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (0.9%). Announcement • Mar 02
Medikit Co.,Ltd. to Report Fiscal Year 2024 Results on May 15, 2024 Medikit Co.,Ltd. announced that they will report fiscal year 2024 results on May 15, 2024 Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: JP¥48.29 (vs JP¥55.53 in 3Q 2023) Third quarter 2024 results: EPS: JP¥48.29 (down from JP¥55.53 in 3Q 2023). Revenue: JP¥6.02b (up 2.2% from 3Q 2023). Net income: JP¥811.0m (down 13% from 3Q 2023). Profit margin: 14% (down from 16% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 2% per year. Announcement • Dec 06
Medikit Co.,Ltd. (TSE:7749) announces an Equity Buyback for 2,200,100 shares, representing 13.1% for ¥5,253.84 million. Medikit Co.,Ltd. (TSE:7749) announces a share repurchase program. Under the program, the company will repurchase up to 2,200,100 shares, representing 13.1% of its share capital, for ¥5,253.84 million. The shares will be repurchased at ¥2,183 per share. The company will repurchase its shares in order to implement a flexible capital policy in response to the business environment. As of September 30, 2023, the company had 16,795,580 shares outstanding (excluding treasury shares) and 2,084,420 shares in treasury. Announcement • Nov 27
Medikit Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024 Medikit Co.,Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024 Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: JP¥45.01 (vs JP¥39.26 in 2Q 2023) Second quarter 2024 results: EPS: JP¥45.01 (up from JP¥39.26 in 2Q 2023). Revenue: JP¥5.30b (flat on 2Q 2023). Net income: JP¥756.0m (up 15% from 2Q 2023). Profit margin: 14% (up from 13% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥35.00 per share at 2.6% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 19 December 2023. Payout ratio is a comfortable 41% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (1.1%). Announcement • Aug 30
Medikit Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023 Medikit Co.,Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023 Reported Earnings • Aug 12
First quarter 2024 earnings released: EPS: JP¥33.60 (vs JP¥32.01 in 1Q 2023) First quarter 2024 results: EPS: JP¥33.60 (up from JP¥32.01 in 1Q 2023). Revenue: JP¥5.55b (up 4.8% from 1Q 2023). Net income: JP¥564.0m (up 5.0% from 1Q 2023). Profit margin: 10% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • May 28
Medikit Co.,Ltd. to Report Q1, 2024 Results on Aug 10, 2023 Medikit Co.,Ltd. announced that they will report Q1, 2024 results on Aug 10, 2023 Announcement • May 17
Medikit Co.,Ltd., Annual General Meeting, Jun 28, 2023 Medikit Co.,Ltd., Annual General Meeting, Jun 28, 2023. Reported Earnings • May 17
Full year 2023 earnings released: EPS: JP¥171 (vs JP¥178 in FY 2022) Full year 2023 results: EPS: JP¥171 (down from JP¥178 in FY 2022). Revenue: JP¥21.6b (up 7.3% from FY 2022). Net income: JP¥2.86b (down 4.3% from FY 2022). Profit margin: 13% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥30.00 per share at 2.5% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.1%). Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: JP¥55.52 (vs JP¥45.28 in 3Q 2022) Third quarter 2023 results: EPS: JP¥55.52 (up from JP¥45.28 in 3Q 2022). Revenue: JP¥5.89b (up 6.5% from 3Q 2022). Net income: JP¥932.0m (up 23% from 3Q 2022). Profit margin: 16% (up from 14% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Nov 27
Medikit Co.,Ltd. to Report Q3, 2023 Results on Feb 10, 2023 Medikit Co.,Ltd. announced that they will report Q3, 2023 results on Feb 10, 2023 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Outside Director Atsuko Otaki was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: JP¥39.26 (vs JP¥43.14 in 2Q 2022) Second quarter 2023 results: EPS: JP¥39.26 (down from JP¥43.14 in 2Q 2022). Revenue: JP¥5.27b (up 4.1% from 2Q 2022). Net income: JP¥659.0m (down 9.1% from 2Q 2022). Profit margin: 13% (down from 14% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Announcement • Aug 31
Medikit Co.,Ltd. to Report Q2, 2023 Results on Nov 11, 2022 Medikit Co.,Ltd. announced that they will report Q2, 2023 results on Nov 11, 2022 Reported Earnings • Aug 12
First quarter 2023 earnings released: EPS: JP¥32.01 (vs JP¥40.17 in 1Q 2022) First quarter 2023 results: EPS: JP¥32.01 (down from JP¥40.17 in 1Q 2022). Revenue: JP¥5.29b (up 7.0% from 1Q 2022). Net income: JP¥537.0m (down 20% from 1Q 2022). Profit margin: 10% (down from 14% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • May 29
Medikit Co.,Ltd. to Report Q1, 2023 Results on Aug 10, 2022 Medikit Co.,Ltd. announced that they will report Q1, 2023 results on Aug 10, 2022 Reported Earnings • May 19
Full year 2022 earnings released: EPS: JP¥178 (vs JP¥157 in FY 2021) Full year 2022 results: EPS: JP¥178 (up from JP¥157 in FY 2021). Revenue: JP¥20.1b (up 4.2% from FY 2021). Net income: JP¥2.99b (up 13% from FY 2021). Profit margin: 15% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • May 18
Medikit Co.,Ltd., Annual General Meeting, Jun 29, 2022 Medikit Co.,Ltd., Annual General Meeting, Jun 29, 2022. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Outside Director Atsuko Otaki was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 08
Medikit Co.,Ltd. to Report Fiscal Year 2022 Results on May 13, 2022 Medikit Co.,Ltd. announced that they will report fiscal year 2022 results on May 13, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (0.9%). Reported Earnings • Feb 12
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: JP¥45.28 (down from JP¥46.43 in 3Q 2021). Revenue: JP¥5.53b (up 5.3% from 3Q 2021). Net income: JP¥761.0m (down 2.8% from 3Q 2021). Profit margin: 14% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Dec 18
Medikit Co.,Ltd. (JASDAQ:7749) announces an Equity Buyback for 144,000 shares, representing 0.86% for ¥400 million. Medikit Co.,Ltd. (JASDAQ:7749) announces a share repurchase program. Under the program, the company will repurchase up to 144,000 shares, representing 0.86% of its issued share capital (excluding treasury stock), for a total purchase price of ¥400 million. The purpose of the program is to implement agile capital policies, improve capital efficiency, and return profits to shareholders in response to changes in the business environment. The program will continue through June 30, 2022. As of September 30, 2021, the company had 16,805,280 issued shares (excluding treasury stock) and 2,074,720 treasury shares. Reported Earnings • Nov 12
Second quarter 2022 earnings released: EPS JP¥43.14 (vs JP¥34.21 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥5.06b (up 4.3% from 2Q 2021). Net income: JP¥725.0m (up 25% from 2Q 2021). Profit margin: 14% (up from 12% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • May 17
Full year 2021 earnings released: EPS JP¥157 (vs JP¥170 in FY 2020) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: JP¥19.3b (down 2.9% from FY 2020). Net income: JP¥2.66b (down 7.9% from FY 2020). Profit margin: 14% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 1% per year. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 29 June 2021. Trailing yield: 1.5%. Lower than top quartile of Japanese dividend payers (2.7%). Higher than average of industry peers (0.7%). Announcement • Mar 04
Medikit Co.,Ltd. to Report Fiscal Year 2021 Results on May 14, 2021 Medikit Co.,Ltd. announced that they will report fiscal year 2021 results on May 14, 2021 Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS JP¥46.43 (vs JP¥48.84 in 3Q 2020) The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: JP¥5.25b (down 4.2% from 3Q 2020). Net income: JP¥783.0m (down 5.4% from 3Q 2020). Profit margin: 15% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has remained flat. Announcement • Nov 29
Medikit Co.,Ltd. to Report Q3, 2021 Results on Feb 10, 2021 Medikit Co.,Ltd. announced that they will report Q3, 2021 results on Feb 10, 2021 Is New 90 Day High Low • Nov 19
New 90-day low: JP¥2,950 The company is down 12% from its price of JP¥3,345 on 21 August 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 13% over the same period. Reported Earnings • Nov 14
Second quarter 2021 earnings released: EPS JP¥34.21 The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥4.85b (down 3.4% from 2Q 2020). Net income: JP¥580.0m (down 14% from 2Q 2020). Profit margin: 12% (down from 13% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 3% per year. Is New 90 Day High Low • Nov 02
New 90-day low: JP¥3,015 The company is down 14% from its price of JP¥3,495 on 04 August 2020. The Japanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 7.0% over the same period. Is New 90 Day High Low • Oct 16
New 90-day low: JP¥3,085 The company is down 11% from its price of JP¥3,450 on 17 July 2020. The Japanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 13% over the same period. Announcement • Aug 30
Medikit Co.,Ltd. to Report Q2, 2021 Results on Nov 12, 2020 Medikit Co.,Ltd. announced that they will report Q2, 2021 results on Nov 12, 2020 